May 07, 2024
Regen BioPharma, Inc. to Present at the Emerging Growth Conference on May 9, 2024
Mar 05, 2024
Regen BioPharma, Inc. to Present at the Emerging Growth Conference on March 7, 2024
Feb 05, 2024
Regen BioPharma, Inc. to Present at the Emerging Growth Conference on February 7, 2024
Nov 01, 2019
Regen BioPharma, Inc. Discovers Fundamental Role of NR2F6 in Production of Malignant Blood Vessels
Oct 03, 2019
Regen BioPharma Successfully Treats Rheumatoid Arthritis Using Cannabidiol (CBD) Based Immune Modulatory Treatments
Aug 07, 2019
Regen BioPharma Inc. Files Immuno-Oncology Patent Application on Synergy of Cannabidiol With NR2F6 Modulation
May 08, 2019
Regen BioPharma, Inc. Responds to Fake News Release
Jan 08, 2019
Regen BioPharma, Inc. Examines Combining Cannabidiol (CBD) With Its Lead NR2F6 Agonist To Treat for Inflammatory Bowel Disease
Nov 13, 2018
Regen BioPharma, Inc. Reports Additional New NR2F6 Small Molecule Inhibitors
Oct 04, 2018
Regen BioPharma, Inc. Determines Its Lead NR2F6 Agonist Ready for Inflammatory Bowel Disease Animal Studies
Sep 21, 2018
Regen BioPharma, Inc. Reports Activation of Immune Cells by Its NR2F6 Small Molecule Inhibitors
Sep 11, 2018
Regen BioPharma, Inc. Updates Report on Success of Its NR2F6 Small Molecule Antagonist Screening Program for Treating Cancer
Sep 06, 2018
Regen BioPharma, Inc. Files New Composition of Matter Patent Application Based on Its Successful Modulation of NR2F6 by Its Small Molecule Compounds
Aug 30, 2018
Regen BioPharma, Inc. Reports Success of its NR2F6 Small Molecule Screening Program for Treating Autoimmune Diseases
Jul 23, 2018
No Toxicity Seen in Mice as Regen BioPharma, Inc. Finishes Initial Optimization of its Lead NR2F6 Small Molecule Agonist
Mar 21, 2018
Regen BioPharma, Inc. Nears Completion of Optimizing its Lead NR2F6 Small Molecule Agonist
Feb 21, 2018
Regen BioPharma, Inc. Program to Determine the 3-D Crystal Structure of NR2F6 Progresses to Next Step
Jan 17, 2018
Regen BioPharma, Inc.'s Medicinal Chemistry Program has Identified Additional Compounds That Activate NR2F6
Dec 11, 2017
Regen BioPharma, Inc. Files Additional Composition of Matter Patent Application on NR2F6-Modulating Small Molecules
Nov 27, 2017
Regen BioPharma, Inc. Begins In Vivo Assessment of Small Molecule Agonists to NR2F6 Nuclear Receptor